Tyme Technologies Inc (OQ:TYME)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 17 State St Fl 7
NEW YORK NY 10004-1585
Tel: N/A
Website: https://www.tymeinc.com
IR: See website
Key People
Business Overview
Tyme Technologies, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body's natural immune system. The Company's lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer, and it is preparing to initiate an additional Phase II clinical trial for pancreatic cancer. The Company provides a novel compound for physicians to use in a treatment regimen for patients fighting six major cancers including breast, lung, prostate, gastric, esophageal and pancreatic cancers.
Financial Overview
For the nine months ended 31 December 2019, Tyme Technologies Inc revenues was not reported. Net loss decreased 25% to $16.3M. Lower net loss reflects Research and development - Balancing val decrease of 38% to $5.4M (expense), Stock-based Compensation in SGA decrease of 37% to $2.7M (expense), Stock-based Compensation in R&D decrease of 11% to $1.9M (expense).
Employees: 15 as of Mar 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $123.66M as of Dec 31, 2019
Annual revenue (TTM): $0.00M as of Dec 31, 2019
EBITDA (TTM): -$26.46M as of Dec 31, 2019
Net annual income (TTM): -$27.47M as of Dec 31, 2019
Free cash flow (TTM): -$17.87M as of Dec 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 122,839,504 as of Jan 28, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization